Kristen Pierce, MD
Infectious Disease · Burlington, VTNPI 1548482102
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, T2 Biosystems, Inc..
Across 1 payment — averaging $76.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- T2 Biosystems, Inc.$76
Across 42 payments — averaging $73,312 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.1M
What the payments were for
- Food & beverage$76100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| T2 Biosystems, Inc. | 1 | $76 |
How this compares
Too few infectious disease providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TivicayDolutegravir Sodium | 57 | $128,268 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 31 | $118,504 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 31 | $117,876 |
| DescovyEmtricitabine/Tenofov Alafenam | 47 | $103,575 |
| SirturoBedaquiline Fumarate | 14 | $53,081 |
| IsentressRaltegravir Potassium | 25 | $47,341 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $34,255 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 12 | $29,182 |
| VemlidyTenofovir Alafenamide | 13 | $18,844 |
| Darunavir | 20 | $16,346 |
| Etravirine | 12 | $12,382 |
| Ritonavir | 17 | $5,780 |
| Lamivudine | 12 | $2,574 |
| Cefpodoxime Proxetil | 12 | $2,305 |
| Ethambutol Hcl | 34 | $923 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Burlington
- Beth KirkpatrickBurlington$5K
- Lindsay SmithBurlington$115
- Wallace AlstonBurlington$18
- Cindy NoyesBurlington$0
- Timothy LaheyBurlington$0
- Andrew HaleBurlington$0
- Mary RamundoBurlington$0
- Peter HysonBurlington$0
- Timothy WhitmanBurlington$0
- Christopher HustonBurlington$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.